

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES





**Defective images within this document are accurate representation of
The original documents submitted by the applicant.**




Defects in the images may include (but are not limited to):


- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**




IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**












a




b




a



b



Author	Year	Sample Size	Age Range	Gender	Location	Study Type	Findings
Smith et al.	2001	150	18-25	Male	USA	Experimental	High levels of stress and anxiety reported.
Johnson et al.	2003	200	26-35	Female	UK	Survey	Significant increase in depression symptoms.
Lee et al.	2005	120	36-45	Male	Canada	Interview	High levels of job dissatisfaction.
Wong et al.	2007	180	46-55	Female	Australia	Survey	Increased levels of burnout and exhaustion.
Chen et al.	2009	220	56-65	Male	China	Experimental	Significant improvement in cognitive function.
Miller et al.	2011	160	66-75	Female	USA	Survey	High levels of social isolation and loneliness.
Ng et al.	2013	140	76-85	Male	UK	Interview	Significant decline in physical health.
Patel et al.	2015	190	86-95	Female	India	Survey	High levels of cognitive decline.
Kim et al.	2017	210	96-105	Male	South Korea	Experimental	Significant improvement in mood and well-being.






PRINT OF DRAWINGS
AS ORIGINALLY FILED




Class I

Class II




Control
DAP.3






hTSHR
DAP.3






RT4.15HP






hTSHR
Transfected
RT4.15HP






dsDNA
Transfected
DAP.3






dsDNA
Transfected
hTSHR DAP.3



dsDNA
Transfected
RT4.15HP



dsDNA
Transfected
hTSHR-RT4.15HP



00
16
01
14
01
14
10
03
05
14
02
03

ds DNA

- +

MHC Class I



TAP1




LMP2



MHC Class II



li



HLA DM



90K



GAPDH



Mice Immunized with
ds DNA-Transfected
hTSHR DAP.3 Cells

A.



B.




C.



D.



Mice Immunized with
hTSHR DAP.3 Cells



PRINT OF DRAWINGS
AS ORIGINALLY FILED

10 20 30 40 50 60 70 80 90 100
gaatttctcgg ccaggaatg gctcttctgt gctcctcttc tgtgttcttg ctggttccag ggaactcaag tcacaaagat ggaagacatgc gcttctttaa 100
MetA IeLeuLeuTr pLeuLeuSer ValPheLeuL euValProGl yThrGlnGly AlaLysAspG iAspMetAr gLeuValAs
TGGGGCCYCA CCAAGGAGG GCGGCHYGA GATCTCTAC AGAAGGCGG GGGGACAC GCGGACAC CTTGGATGC CCACTCTCTC 200
nGlyAlaSer ProSerGluG IyArgValGl uillePheTyr ArgGlyArgT rpGlyThrLe uCysAspAen LeuTrpAenL euLeuAspAl eHieValPhe
TGGGGGGCC TGGGAYGA YATGAYAC CCAACATGA ACAGAGTGC CTTGGGCGCA GGAAGGGAC CAATCATGC GATAGAGTG GAATGACAG 300
CysArgAlaL euGlyTyrAs pAenAlaThr ProAlaLeuA enArgValAl ePheGlyPro GlyLysGlyP rolleMette uAspGluVal GluCysThrG
GGAAGGAGTC GYCATGGCC AATGGAGGT CCGTGGCTG GATGGGAGC CACTGGGCG AYAGAGGAA CCGGGGCTG GTCGGGCA ACATGCGAG 400
IyGluLeu rSerLeuAla ePheCysSerS erLeuGlyTr pMetValSer HieCysGlyH IeGlyLysAs pAlaGlyVal ValCysSerA eAspSerAr
GGCATTAC ATCTAGACC TCTCTGAGGA GCTTCCAGAT TCACTGGCC AGATCTTTGA CAGCCAGCAG GACTGCGACC TGTTCATCCA GGTGACAGGG 500
gGlylleHie IieLeuAspL euSerGlyGl uLeuProAsp SerLeuGlyD IillePheAs pSerGlnGln AspCysAspL euPheileGl nValThrGly
CAGGACATG GGGACCTGAG CCTCTGTGCC CACACACTGA TCCTGGCCAC CAACCCCGAG GCCCAGGCCC TGTGGCAAGT GGTGGGCAAG AGTGTCTCA 600
GlnGlyHieG IyAspLeuS rLeuCysAla HieThrLeuL IeLeuArgTh rAenProGlu AlaGlnAlaL euTrpGlnVa IValGlySer SerValilleM
TGAAGATGA CCGTGAATGC ATGCTGTGCG TCAGAGACTT CCTCAGGTAC TTTTACTCCC GAAGAAATGA GGTGAGCATG TCTTCTGTCA AGTGTCTGCA 700
etArgValAs pAlaGluCys MetProValV eIArgAspPh eLeuArgTyr PheTyrSerA rgArgilleGl uValSerMet SerSerValL ysCysLeuHie
CAAGCTGGCC TCGCCCTATG GAAGCAGAGA GCTCCAGGT TACTGTGAG GCTTTTTGT CACCCCTCCT CCCCAGGACC CCACCTTCCA TACGCCCTG 800
eLysLeuAla SerAlaTyrG IyAlaThrGl uLeuGlnGly TyrCysGlyA rGluPheVa IThrLeuLeu ProGlnAspP reThrPheHie uThrProLeu
GAAGTTTAC AGTATGGCA GGGCAGCGG GACTCTGCG TGAAGATCT GTGTGTCAA TTCCTGGCT GGAAGTGA CCGCTGACA CAGGCCGAGT 900
GluLeuTyrG IuTyrAlaGl nAlaThrGly AspSerValL euGluAspLe uCysValGln PheLeuAlaT rpAenPheGl uProLeuThr GlnAlaGluS
CCTGTTGTC TGTTCGAAT GCCTGATCC AAGCTCTCT CCCCAGGAGC GAGCTGGCTG TGTCTAGTGA ACTGGATTTG CTGAAGGCAAG TGGACCAAGT 1000
erTrpLeuS rValProAen AlaLeuileG InAlaLeuL uProLysSer GluLeuAlaV eIerSerGl uLeuAspLeu LeuLysAlaV eIAspGlnTr
GAGCAGAGC ACCGGCCCT CCCACGGGA TGTAGGCG CTGGTGAAG AGATCCGCT TCTATGATG CTGCCCCAGG AGCTGTTTGA GCTACAGTTC 1100
pSerThrAla ThrGlyAlaS uHieGlyAs pValGluArg LeuValGluD IilleArgPh eProMetMet LeuProGlnG IuLeuPheGlu LeuGlnPhe
LAAGCTGTCT TGTACCAAG TCACCAAGCC CTGTTCCAGA GGAAGACCAT GAGGCGCTG GAGTTCACA CAGTGCTCT CAAAGTGCTG GCCAAGTACA 1200
eLeuSerL euTyrGlnGl yHieGlnAla LeuPheGlnA rGlyThrMe tGluAlaLeu GluPheHieT hrValProLe uLysValLeu AlaLysTyrA
GAAGCCTGAA CCTACCGAG GATGTCTACA AACCCCGCT TTACACCTCT TCTACCTGGA GTAAGCTGCT GATGGCCGCT GCCTGGAGTA CACAAAGCTA 1300
rGSerLeuAspLeuThrGlu AspValTyrL ysProArgLe uTyrThrSer SerThrTrpS rSerLeuLe uMetalaGly AlaTrpSerT hrGlnSerTy
CAATACAGA GAGTTCTACA CATACAATA TGCTCAGAA TCCGCTACA GCACTACCA GAAGTTCCA ACCCCACAAC ACCCCAGCTT CCTCTTCAA 1400
rLysTyrArg GlnPheTyrT hrTyrAenTy rGlySerGln SerArgTyrS rSerTyrGl nAenPheGln ThrProGlnH IeProSerPh eLeuPheLys
GACAACTGA TCTCTGCTC AGCCACCTAC CTGCCACCA TCCAGAGTTG CTGGAAGTAT GCTTCTCTGT GTACCTCTGA CAGCTCCCT GTACTGGGCC 1500
AspLysLeuL IeSerTrpS rAlaThrTyr LeuProThrI IeGlnSerCy sTrpAenTyr GlyPheSerC ysThrSerAs pGluLeuPro ValLeuGlyL
TCACCATC CAGTTACTCC GATCCAATA TCGGCTACA GAACAAAGCG CTGATCTCT GTGGAGGCTA CAGTGTGTA GATGTACCA CTTTATAGG 1600
eThrThrS rSerTyrSer AspProThrI IeGlyTyrGl uAenLysAla LeuileLeuC ysGlyGlyTy rSerValVal AspValThrT hrPheileGl
CTCTAAGGCC CCTATTCCAG GTACCCAGGA GACCAATAGT TCCAGAGCC CCGCTCTCT TCCCTGTGCG TCAAGGCGCT TCAGCAAGCT CCGCTGGTC 1700
ySerLysAla PreileProG IyThrGlnGl uThrAspSer SerLysThrP reSerLeuPh eProCysAla SerGlyAlaP heSerSerPh eArgValVal
ATCCGCCCT TCTACCTCAC CAATCCACT GACACGAGT AGATggtaa tctagggtt gggagcttg aattctctgt gtctctctat tggctcttg 1800
IleArgProP heTyrLeuTh rAspSerThr AspThrGlu
ctctctgtt ggaactttaa ggaactttaa ccaagcttga ctttagctta aattgtctat atgagcttga aattgtctat ggaagcttga ggaagcttga 1900
actctagat ctgagagtat agggctctaa attgtagga gaaaggggtt atgtgggtt tctctcttg tctctcttg tctctcttg tctctcttg 2000
ggcaggtgt tctctg


[illegible]

Year	Age	Sex	Height (cm)	Weight (kg)	Body Mass Index (kg/m ²)	Waist Circumference (cm)	Hip Circumference (cm)	Waist-Hip Ratio	Trunk Fat (%)	Visceral Fat (cm ³)	Subcutaneous Fat (cm ³)	Visceral Fat Index (cm ³ /m ²)	Subcutaneous Fat Index (cm ³ /m ²)	Visceral Fat to Subcutaneous Fat Ratio
1991	27	M	175	75	24.5	95	105	0.90	15	150	100	1.5	1.0	1.5
1992	28	M	176	78	24.8	96	106	0.90	16	160	110	1.6	1.1	1.5
1993	29	M	177	80	25.1	97	107	0.90	17	170	120	1.7	1.2	1.5
1994	30	M	178	82	25.4	98	108	0.90	18	180	130	1.8	1.3	1.5
1995	31	M	179	84	25.7	99	109	0.90	19	190	140	1.9	1.4	1.5
1996	32	M	180	86	26.0	100	110	0.90	20	200	150	2.0	1.5	1.5
1997	33	M	181	88	26.3	101	111	0.90	21	210	160	2.1	1.6	1.5
1998	34	M	182	90	26.6	102	112	0.90	22	220	170	2.2	1.7	1.5
1999	35	M	183	92	26.9	103	113	0.90	23	230	180	2.3	1.8	1.5
2000	36	M	184	94	27.2	104	114	0.90	24	240	190	2.4	1.9	1.5
2001	37	M	185	96	27.5	105	115	0.90	25	250	200	2.5	2.0	1.5
2002	38	M	186	98	27.8	106	116	0.90	26	260	210	2.6	2.1	1.5
2003	39	M	187	100	28.1	107	117	0.90	27	270	220	2.7	2.2	1.5
2004	40	M	188	102	28.4	108	118	0.90	28	280	230	2.8	2.3	1.5
2005	41	M	189	104	28.7	109	119	0.90	29	290	240	2.9	2.4	1.5
2006	42	M	190	106	29.0	110	120	0.90	30	300	250	3.0	2.5	1.5
2007	43	M	191	108	29.3	111	121	0.90	31	310	260	3.1	2.6	1.5
2008	44	M	192	110	29.6	112	122	0.90	32	320	270	3.2	2.7	1.5
2009	45	M	193	112	29.9	113	123	0.90	33	330	280	3.3	2.8	1.5
2010	46	M	194	114	30.2	114	124	0.90	34	340	290	3.4	2.9	1.5
2011	47	M	195	116	30.5	115	125	0.90	35	350	300	3.5	3.0	1.5
2012	48	M	196	118	30.8	116	126	0.90	36	360	310	3.6	3.1	1.5
2013	49	M	197	120	31.1	117	127	0.90	37	370	320	3.7	3.2	1.5
2014	50	M	198	122	31.4	118	128	0.90	38	380	330	3.8	3.3	1.5
2015	51	M	199	124	31.7	119	129	0.90	39	390	340	3.9	3.4	1.5
2016	52	M	200	126	32.0	120	130	0.90	40	400	350	4.0	3.5	1.5
2017	53	M	201	128	32.3	121	131	0.90	41	410	360	4.1	3.6	1.5
2018	54	M	202	130	32.6	122	132	0.90	42	420				


(%S+G2/M phase)

03
03
14
09
14
03
14
10
03
03
14
03
03
03


Control
(22.4%)




MMI
(58.3%)



MMI
+dsDNA
(35.6%)







MMI
+dsRNA
(2.04%)




PRINT OF DRAWINGS
AS ORIGINALLY FILMED

PROTEIN MEASURED BY ECL BLOT WITH ANTIBODY







A




B



C




D



00
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99

A



B




Fig 7

02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

